Correlation Between Genmab AS and Novo Nordisk

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Genmab AS and Novo Nordisk at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Genmab AS and Novo Nordisk into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Genmab AS and Novo Nordisk AS, you can compare the effects of market volatilities on Genmab AS and Novo Nordisk and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Genmab AS with a short position of Novo Nordisk. Check out your portfolio center. Please also check ongoing floating volatility patterns of Genmab AS and Novo Nordisk.

Diversification Opportunities for Genmab AS and Novo Nordisk

0.94
  Correlation Coefficient

Almost no diversification

The 3 months correlation between Genmab and Novo is 0.94. Overlapping area represents the amount of risk that can be diversified away by holding Genmab AS and Novo Nordisk AS in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Novo Nordisk AS and Genmab AS is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Genmab AS are associated (or correlated) with Novo Nordisk. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Novo Nordisk AS has no effect on the direction of Genmab AS i.e., Genmab AS and Novo Nordisk go up and down completely randomly.

Pair Corralation between Genmab AS and Novo Nordisk

Assuming the 90 days trading horizon Genmab AS is expected to under-perform the Novo Nordisk. But the stock apears to be less risky and, when comparing its historical volatility, Genmab AS is 1.07 times less risky than Novo Nordisk. The stock trades about -0.08 of its potential returns per unit of risk. The Novo Nordisk AS is currently generating about 0.07 of returns per unit of risk over similar time horizon. If you would invest  43,977  in Novo Nordisk AS on August 24, 2024 and sell it today you would earn a total of  31,113  from holding Novo Nordisk AS or generate 70.75% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthVery Strong
Accuracy100.0%
ValuesDaily Returns

Genmab AS  vs.  Novo Nordisk AS

 Performance 
       Timeline  
Genmab AS 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Genmab AS has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain very healthy which may send shares a bit higher in December 2024. The recent disarray may also be a sign of long period up-swing for the firm investors.
Novo Nordisk AS 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Novo Nordisk AS has generated negative risk-adjusted returns adding no value to investors with long positions. Despite unfluctuating performance in the last few months, the Stock's basic indicators remain somewhat strong which may send shares a bit higher in December 2024. The current disturbance may also be a sign of long term up-swing for the company investors.

Genmab AS and Novo Nordisk Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Genmab AS and Novo Nordisk

The main advantage of trading using opposite Genmab AS and Novo Nordisk positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Genmab AS position performs unexpectedly, Novo Nordisk can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Novo Nordisk will offset losses from the drop in Novo Nordisk's long position.
The idea behind Genmab AS and Novo Nordisk AS pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..

Other Complementary Tools

Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Sign In To Macroaxis
Sign in to explore Macroaxis' wealth optimization platform and fintech modules
Top Crypto Exchanges
Search and analyze digital assets across top global cryptocurrency exchanges